fbpx

A/Prof Helen Benson

A/Prof Helen Benson is an accredited consultant pharmacist with more than 20 years pharmacy experience. Her varied career has included working as a hospital pharmacist, military pharmacist in the Royal Australian Airforce, community pharmacist and as a community pharmacy owner. Currently A/Prof Helen Benson is working as a Senior Lecturer in Pharmacy Practice teaching Master of Pharmacy Students at the University of Technology Sydney. A/Prof Helen Benson has a particular interest in improving patient therapy through medication reviews and continues to work as a consultant pharmacist providing medication reviews for referring general practitioners. In 2019 A/Prof Helen Benson completed a PhD investigating the integration of pharmacists in general practice teams in Australia. A/Prof Helen Benson’s current research is focussed on expanding scope of practice within the profession to allow pharmacists to perform their role as medication experts.

Bridget Totterman

Bridget Totterman B.Pharm; GAICD, MPS  joined the PSA board in 2023.

 

Bridget is a registered pharmacist and community pharmacy owner with over 15 years’ experience in whole of business management including operations and frontline leadership.

 

She is a graduate of the Australian Institute of Company Directors (GAICD).

 

Bridget is a member of the Australian Community Pharmacy Authority (ACPA) and is a member of the Queensland branch committee for the Pharmaceutical Society of Australia.

 

Bridget was awarded with the Bowl of Hygiea – QLD Pharmacist of the Year in 2020 for outstanding leadership and change management.

 

Bridget was a member of the Steering Advisory Group (SAG) for UTIPP-Q (2020-2022) and was a vaccinating pharmacist in QPIP (2014). She is credentialed to administer injections and immunisations. Bridget was appointed Clinical Fellow of Queensland University of Technology in 2018 and is a member of the Course Advisory Group for QUT Bachelor of Pharmacy (Hons.).

 

Bridget has completed courses in Directorships; Management; Marketing; Successful Negotiations; Human Resources and has an Associate Diploma in Speech and Drama.

A/Prof Fei Sim

A/Prof Fei Sim is the first female National President to lead PSA since its Federation in 1977. A/Prof Sim is a Senior Lecturer and the Coordinator of International Engagement in the Curtin Medical School at Curtin University, Western Australia (WA).

 

In 2020 she was also made a Fellow of the Society before being appointed as a Director on the PSA National Board in 2021. A/Prof Sim has over 14 years of clinical practice experience and is currently a practising community pharmacist and a community pharmacy proprietor. A/Prof Sim also served as PSA’s WA President from 2017 to 2021.

 

A/Prof Sim holds a Doctor of Philosophy degree in Pharmacy and a Bachelor of Pharmacy degree with First Class Honours and is a qualified pharmacist immuniser and an Accredited Mental Health First Aid Instructor. She is a Fellow of the PSA and the Higher Education Academy, and a Graduate Member of the Australian Institute of Company Directors. A/Prof Sim serves on a number of professional and academic committees.

 

A/Prof Sim was awarded the Excellence and Innovation in Teaching Award in 2014, the PSA WA Early Career Pharmacist Award in 2018 and the National Early Career Pharmacist of The Year Award in 2019, all of which are testament to her commitment to patient care, learning and teaching, leadership in pharmacy, innovation and initiative in pharmacy service delivery, as well as peer and professional engagement.

 

A/Prof Sim is an active pharmacy practice researcher and is also the recipient of a number of research grants and projects focusing on advancing the practice of pharmacy and the implementation of professional pharmacy services in community pharmacy, including the noteworthy JM O’Hara Research Fund grant from the Pharmaceutical Society of West Australia (PSWA) in 2018. Through this grant, A/Prof Sim and her team conducted and published on a feasibility study on point-of-care C-reactive protein testing in community pharmacy. It is hoped this project will contribute towards facilitating antimicrobial stewardship and advancing evidence-based community pharmacy practice to improve recognition of pharmacists’ roles and remuneration.

Prof Mark Naunton

Prof Mark Naunton is currently Head of the School of Health Sciences and Professor of Pharmacy at the University of Canberra and teaches primarily in therapeutics and pharmacy practice. His career includes: academic, community pharmacy, hospital pharmacy, and accredited pharmacist in Tasmania, Northern Territory, and the ACT. Prof Mark Naunton has a wide-reaching interest in the pharmacy profession and has worked internationally as a post-doctoral fellow at the University of Groningen in the Netherlands. He is credentialed to undertake medication reviews and occasionally practice in community pharmacy.

 

Prof Mark’ Naunton’s recent research has focused on expanding the scope of practice of pharmacists and has supervised several PhD candidates in two relevant areas: evaluating the impact of pharmacists working in general practice and RACFs.

 

He has served on the Tasmanian PSA Branch committee (2000-2001) and the South Australian/Northern Territory PSA Branch committee (2008-2010).

 

Prof Mark Naunton has been on the PSA ACT branch committee since 2017 and served on the PSA National Board since 2022 and graduated from the Australian Institute of Company Directors in 2022.

 

Prof Mark Naunton has been a PSA member for 20 years and an active member of the pharmacy profession for over 25 years. He undertook one of the first clinical trials in Australia evaluating the benefits of HMRs post-discharge. He has also been involved in various evaluations of community pharmacist screening (osteoporosis) and disease management (cardiovascular disease. Mark is passionate about medication safety and firmly believes pharmacists are the most suited professional to ensure this occurs.

Caroline Diamantis

Caroline Diamantis is a passionate community pharmacist with over 30 years of experience in pharmacy ownership.

 

Shortly after completing her Bachelor of Pharmacy at Sydney University, she was able to fulfil her dream of buying her first pharmacy, where she realised the importance of differentiating pharmacists as professionals, advocating clinical pharmacy and the professional services model.

 

Caroline went on to become a director on the board of Blooms the Chemist, where she spent several years advocating for female pharmacy owners and gender diversity in industry leadership positions, and mentoring early career pharmacists (ECPs) into ownership roles with programs designed to support and engage.

 

Caroline was elected as Vice President of the NSW Pharmacy Guild in 2017. In this role she continued advocating for community pharmacy, particularly clinical pharmacy, and for pharmacists to be acknowledged and remunerated fairly for their role in primary health care and the critical difference they make to health outcomes.

 

Other Pharmacy Guild positions have included chairperson of the Viability sub-committee and Finance and Risk sub-committee, and alternate National Councillor.

 

Caroline is a passionate advocate for recognition of the profession during crisis, seeking acknowledgement and financial support from the NSW government. She is committed to addressing workforce issues, including mentorship to ECPs and support and advocacy for appropriate pharmacist salaries, and determined to achieve full scope of clinical practice.

Code of Ethics review

July 2025 to June 2026

The Pharmaceutical Society of Australia (PSA), in partnership with the Department of Health, Disability and Ageing, is undertaking a review, update and further development of the Code of Ethics for Pharmacists (the ‘Code’).  The Code is a fundamental resource that articulates the values of the pharmacy profession and expected standards of ethical behaviour of pharmacists towards individuals, the community and society. The Code underpins the professional practice of all pharmacists in Australia.

 

The core objectives are to:

  • review, revise and further develop the Code to align with contemporary pharmacy practice and the expectations of the profession and the wider community
  • deliver a revised Code with increased clarity on emerging ethical issues (e.g. broadening scope of practice, increased compounding, expansion of digital systems that provide clinical information to pharmacists)
  • support pharmacists to implement the revised Code to enable pharmacists to continue to provide the highest quality of care in their daily practice.

This project commenced on 1st July 2025 and will conclude 30th June 2026. Key dates:

  • July – October 2025 – Stakeholder Engagement & Consultation
  • March – April 2026 – Public Consultation of the revised Code draft
  • June 2026 – Launch of revised Code
  • July 2026 – National Webinar

Have feedback or insights?

You can either submit the form below or call 1300 369 772 and select “Code of Ethics review project” (option 6), leave a message and the PSA team will contact you.

From the President

At the heart of our profession is our shared commitment to Care, Competency, and Integrity. These ethical values define who we are as pharmacists, guiding our decisions, shaping our relationships with patients, and underpinning the trust our communities place in us.

 

It is these three values that are the foundation of the Pharmacists Code of Ethics.

 

The Code of Ethics, last updated in 2017, must continue to evolve alongside the changing world in which we practice. As pharmacy practice continues to grow and diversify, the ethical challenges we face also become more complex. New models of care, greater prescribing authority, advances in digital health, and the growing role of pharmacists in compounding all bring opportunities, but also new responsibilities.

 

In our role as the custodians of the profession’s ethics, standards, and guidelines, PSA has embarked on a major project to revise and further develop the Code of Ethics – the first project delivered as part of the Strategic Agreement on Pharmacist Professional Practice.

 

This is not work we are doing alone. We are guided by a Project Advisory Group (PAG) made up of truly remarkable pharmacists and consumer representatives from across our profession and health sector, including:

  • Dr Ayomide (Mide) Ogundipe – PAG Chair; PSA Board Director
  • Professor Lisa Nissen – HERA Program Director, Health Workforce Optimisation, The University of Queensland
  • Associate Professor Sue Kirsa – Director of Pharmacy, Monash Health
  • Associate Professor Betty Chaar – Chair, Professionalism Committee, The University of Sydney, Fellow of the International Federation of Pharmacy and Chair of the FIP Ethics Expert Group and a Pharmacist Peer Reviewer for the Healthcare Complaints Commission NSW Australia.
  • Naomi Lim – Professional Officer, Pharmaceutical Defence Limited (PDL)
  • Toby Speare – Board Member, Pharmacy Board of Australia
  • Elsa Hietbrink – Director, Pharmacy Agreements & Governance, Dept of Health, Disability & Ageing
  • Radhika Jadav – Pharmacist Policy Officer, Pharmacy Guild of Australia
  • Associate Professor Bhavini Patel – Advanced Pharmacy Australia (AdPha) Leadership and Management Committee, Executive Director, Medicines Management, NT Health
  • Sebastian Harper – National President, National Australian Pharmacy Students’ Association (NAPSA)
  • Mike Stephens – National Aboriginal Community Controlled Health Organisation (NACCHO)
  • Dr Andreia Bruno-Tomé – Director, Research, Policy and Partnerships, Australian Pharmacy Council (APC)
  • Associate Professor Richard Matthews – Associate Professor of Medical Ethics, Bond University
  • Bente Hart – Remote and Isolated Pharmacist Association Australia (RIPAA)
  • Nathan Cruickshank – Professional Pharmacists Australia (PPA)
  • Nicky Bath – Consumer Representative
  • Prudence Buist – Consumer Representative

 

By updating our profession’s Code of Ethics, we are continuing to support all pharmacists to navigate the increasingly complex challenges we face. This breadth of expertise ensures the refreshed Code will be rigorous, practical, and responsive to the needs of our profession and the communities we serve.

 

Best wishes,

Associate Professor Fei Sim FPS
PSA National President

PSA signs agreement to acquire the Australasian College of Pharmacy

Update: The acquisition was finalised on 19 December. See here for details.

The Pharmaceutical Society of Australia (PSA) is excited to announce an agreement to acquire the Australasian College of Pharmacy (ACP) was signed on 20 October 2025. The acquisition of ACP is part of PSA’s plan to expand educational opportunities, and grow PSA’s role as the premier education and training provider for pharmacists, pharmacy assistants and technicians. 

 

There are still steps to be completed before the settlement of the acquisition. It is expected that the acquisition it will be finalised by the end of the year (2025). 

Frequently Asked Questions

Why has the PSA Board decided to acquire ACP?

The decision to acquire ACP is part of the PSA Board’s broader plan to maximise member value through growth, expanding education opportunities for the profession, and securing a long-term, sustainable future for PSA as the premier training and education provider for pharmacists and pharmacy assistants and technicians.

What steps have been taken to progress the acquisition and when will it be finalised?

At the PSA Special General Meeting on 19 February 2025, PSA members voted overwhelmingly (95%) in support of constitutional amendments to enable the acquisition of the ACP. 

 

PSA proceeded to negotiate the terms of the acquisition and the finalisation of the Shares Purchase Agreement with the current shareholders of the ACP. 

 

PSA proceeded to ensure all regulatory issues were addressed. 

 

On 20 October 2025 the PSA Board voted unanimously to enter into a Share Purchase Agreement (contract) with shareholders of the ACP to formally acquire the ACP. 

 

Before final settlement occurs, additional legal matters related to the Share Purchase Agreement will be addressed, with the expectation the acquisition is finalised before the end of the calendar year. 

Will there be any changes to PSA's product offerings?

Until the acquisition is finalised, PSA’s products and services will continue unchanged. 

 

Once the acquisition has been completed, PSA’s education offering and CPD library is expected to grow as more resources can be invested in our education capabilities. 

 

PSA’s objects and mandate as the peak body representing all pharmacists will not change. This means, PSA will continue to be the body representing and supporting all pharmacists across all areas of practice. 

What does this mean for PSA members?

Until the acquisition is finalised, PSA’s products and services will continue to be provided to members unchanged.  

 

Once the acquisition has been completed, PSA’s education offering and CPD library is expected to grow as more resources can be invested in our education. 

 

PSA members can expect greater support and increased focus on high quality education to meet the growing needs of pharmacists in all areas of practice, and the broader pharmacy workforce.

Where can I find out more information if I have questions?

If you have questions regarding PSA’s acquisition of ACP, you can: 

  • call our membership team on 1300 369 772 (business hours AEDT) 

National uniformity for pharmacists administering medicines

6 September 2024

 

The Pharmaceutical Society of Australia (PSA) has welcomed confirmation by the South Australian Office of the Chief Pharmacist (OCP) that pharmacists in South Australia can administer medicines to their patients. This marks an important milestone in establishing national consistency in pharmacists’ scope of practice, enabling pharmacists to administer medicines across all Australian states and territories. It also empowers pharmacists to continue delivering essential healthcare services to their communities.

 

Dr Manya Angley FPS, PSA SA/NT President, welcomed the confirmation by the OCP, noting that it brings the nation one step closer to a more accessible, patient-centred healthcare system.

 

“This is a significant outcome for patients and pharmacists,” said Dr Angley. “By enabling pharmacists in South Australia to administer medicines, we are providing more opportunities for patients to access timely care and improve health outcomes, bringing our scope in line with other jurisdictions.”

 

“Confirmation by the OCP that pharmacists in SA can administer medicines aligns with PSA’s visionary roadmap for the future of pharmacy practice in Australia in Pharmacists in 2030, which advocates for legislative and practice changes to allow pharmacists to prescribe and administer a greater range of medicines.”

 

“Pharmacists are highly trained and trusted healthcare professionals, and we are ready to fulfil these expanded responsibilities,” said PSA National President, Associate Professor Fei Sim FPS. “We call on governments to continue working with the profession and take active steps to enable necessary changes to be implemented, ultimately improving patient access to care whilst maintaining standards, professionalism and quality.”

 

PSA has a range of educational resources available for pharmacists wishing to build their competence in administering medicines, including the Administering Medicines by Injection Course and Guidelines for pharmacists administering medicines by injection.

 

As part of the long-term vision for improving access to medicines and reducing pressure on the healthcare system, PSA remains committed to advocating for further enhancements to pharmacists’ scope of practice.

 

PSA’s recently launched Pharmacists in 2030 vision can be found here: www.psa.org.au/advocacy/working-for-our-profession/pharmacists_in_2030/

New South Wales expands the role of community pharmacists

6 September 2024 

The Pharmaceutical Society of Australia (PSA) welcomes the announcement from New South Wales Health Minister Ryan Park, improving access to medicines through the expansion of pharmacists’ scope of practice in NSW.

The NSW Government will enable pharmacists to provide treatment for a broader range of common and mild conditions, including ear infections, nausea and vomiting, reflux, acne, muscle pain and wound management.

PSA NSW President Luke Kelly FPS welcomed the decision which will allow pharmacists to improve access to healthcare across the state.

“PSA has long advocated for expanding pharmacists’ scope of practice in NSW, and we are grateful for the trust placed in pharmacists by the NSW Government following the success of the NSW Pharmacy Trial,” Mr Kelly said

“It is encouraging to see pharmacists’ accessibility and skills leveraged to provide NSW residents with more timely and accessible health care for a broader range of conditions. This will make our health system more efficient and safer.’’

“The recognition of Queensland trained pharmacists being able to offer these services in NSW is a positive step. National harmonisation of training requirements will cut red tape and enable more pharmacists to deliver essential services to their communities.”

“PSA will continue to work collaboratively with Minister Park and the NSW Government to ensure these services are implemented professionally, effectively and safely.” he said.

PSA National President, Associate Professor Fei Sim FPS commended the NSW Government for recognising pharmacists’ expertise as pharmacists continue to play a vital role in supporting community health.

“PSA supports improving timely and equitable access to care for all Australians through the expansion of prescribing by pharmacists in a rigorous, robust and responsible manner,” said A/Prof Sim.

 

“PSA remains committed to preparing the workforce by providing training, education, and practice support to upskill pharmacists, ensuring they are equipped to deliver these services effectively.”

“This announcement follows the launch of Pharmacists in 2030, PSA’s vision for the future of pharmacist practice.  Expanding pharmacists’ scope to deliver greater access to healthcare to address unmet health needs is a key step towards realising this vision.”

PSA’s Pharmacists in 2030 vision can be found here: https://www.psa.org.au/advocacy/working-for-our-profession/pharmacists_in_2030/ 

International Overdose Awareness Day: Addressing the Emergence of Nitazines and Enhancing Access to Naloxone through Pharmacies

30 August 2024

 

As International Overdose Awareness Day on 31 August approaches, it is a reminder of the critical importance of raising awareness about overdose prevention, reducing stigma around drug-related deaths and acknowledging the loss of families affected by substance use disorder.

This year the focus of pharmacists extends to new and emerging challenges, including the emergence of nitazines in Australia and the continued efforts to expand life-saving measures, such as the Take Home Naloxone program.

Emergence of Nitazines in Australia

In recent months, there has been an increase in the detection of nitazines in Australia.

Nitazines are a group of synthetic opioids which are significantly more potent than fentanyl, posing a heightened risk of overdose and death. Nitazines have been found in a variety of illicit drugs, including non-opioid substances, and in many cases, people have unknowingly consumed them.

The introduction of nitazines has been noted in several reports and the threat they pose underscores the need for increased vigilance, public education and proactive measures to prevent overdoses.

Take Home Naloxone Program: A Life-Saving Initiative

The federal Government has expanded the Take Home Naloxone program, fully funding the availability of naloxone and ensuring there are no out-of-pocket costs for people who may experience  or witness an overdose.

This initiative is a critical step in reducing overdose deaths, ensuring that individuals at risk of opioid overdose, their friends and family members have ready access to this life-saving medication.

 

Community pharmacists play a vital role in the program’s success, serving as accessible points for the distribution of naloxone. However, only around two thirds of Australian pharmacies are currently stocking this critical medicine.

By increasing access to naloxone, more Australians can be empowered to respond effectively in the event of an overdose, potentially saving countless lives.

New resources to assist pharmacists in conversations about opioid use and medicines safety are available at www.psa.org.au/opioidsafety.

Drug Checking – an opportunity to do more

In addition to promoting overdose prevention through naloxone access, the Pharmaceutical Society of Australia (PSA) continues to advocate for the implementation of drug checking services across Australia.

PSA first published a position on drug checking in 2019 and continues to support advocacy for regulation review.

PSA supports the introduction of drug checking to further enhance public health and safety, especially because new and dangerous substances like nitazines have entered the market.

Raising Further Awareness

PSA’s recently released vision for the profession, Pharmacists in 2030, articulates six actions to realise the vision. One key action is Access to Care, supporting pharmacists to provide all consumers greater access to care by increasing and leveraging their accessibility to address unmet health needs.

 

PSA President, Associate Professor Fei Sim, said “Pharmacists, as medicine experts, are essential in mitigating the risk of overdose linked to both medicines and illicit substances. Whether it is participation in the Take Home Naloxone program or actively contributing to opioid stewardship and improved quality use of medicines, pharmacists’ vital role and contribution in community pharmacies, hospitals, aged care facilities, and other primary care areas should not be overlooked.”

“International Overdose Awareness Day presents an opportunity for the community, healthcare professionals, policymakers and the media to continue raising awareness about the risks of opioid overdose, the emergence of new threats, such as nitazines, and the importance of harm reduction strategies.”

“PSA encourages support for initiatives including the Take Home Naloxone program and the adoption of drug checking services, which are vital to efforts to save lives and reduce the impact of drug-related harm.”

 

Pharmacists in 2030 is available to pharmacists and the public at www.psa.org.au/pharmacists_in_2030